Vector Science and Therapeutics Corp. (TSXV: PAIN), headquartered in Mequon, Wisconsin, develops and sells novel biomechanical devices and active localized drug-delivery platforms. The company offers products and services based on its Smart, Steered, and Sustained framework for site-directed interventions in musculoskeletal tissue regeneration. Founded in 2024, the company focuses on pharmaceutical-grade peptide formulations and therapeutic ultrasound platforms designed to address pain management, tissue repair, and cellular recovery.
Vector completed its TSXV listing in April 2026, marking its entry into Canadian public capital markets. The company has entered into a development and manufacturing agreement with MPP Group LLC to develop and manufacture pharmaceutical-grade peptides and drug delivery devices. Vector recently announced an exclusive licensing and manufacturing agreement with LyoGenesis Plus for its proprietary peptide portfolio.
Recent Leadership News
In July 2026, Vector announced that Darryl Drake Jr. serves as President of Valor, its athlete and performance division. The company also appointed Dr. Alexander Dobranowski and Scott Kelly to its Board of Directors in May 2026.
This is an automatically generated Light company page created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.
Facts compiled by Executive Moves from publicly available news and press releases on 9 July 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Vector Science and Therapeutics Corp. team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
